tirzepatide cardiovascular outcomes Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats

Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism

29.35

★★★★☆4.8 (126)

💉 In a large real-world study, tirzepatide was associated with a lower incidence of major cardiovascular outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart

28.30

★★★★★4.9 (98)

SUMMIT trial results presented at #AHA24 show tirzepatide reduced the risk of worsening heart failure events and improved quality of life in patients with #HFpEF and obesity. “Cardiologists now have an ever-expanding

27.06

★★★★★5.0 (157)

Original Article: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT)

26.51

★★★★★4.7 (84)

Tirzepatide linked to lower risk for death, adverse CV and kidney outcomes vs. GLP-1s

28.13

★★★★★4.9 (203)

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes @NEJM Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to a composite of

29.20

★★★★★5.0 (176)

💉 In a large real-world study, tirzepatide was associated with a lower incidence of major cardiovascular outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart

20.77

★★★★★4.8 (132)